Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.33 |
| ▸ | PCK1 | P35558 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 4/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566769 | 1.00 | SCN9A (0.34) | SCN9AHTR1AHTR7EGFRJAK2 | |
| SCHEMBL24309559 | 0.95 | SCN9A (0.36) | SCN9AHTR1AHTR7EGFRJAK2 | |
| SCHEMBL29567274 | 0.95 | SCN9A (0.36) | SCN9AHTR1AHTR7EGFRJAK2 | |
| SCHEMBL24309541 | 0.90 | HTR1A (0.34) | SCN9AHTR1AHTR7JAK2PCK1 | |
| SCHEMBL29567070 | 0.90 | SCN9A (0.40) | SCN9AHTR1AHTR7JAK2FLT4 | |
| SCHEMBL24310783 | 0.90 | SCN9A (0.40) | SCN9AHTR1AHTR7JAK2FLT4 | |
| SCHEMBL29566773 | 0.89 | SCN9A (0.34) | SCN9AHTR1AHTR7JAK2PCK1 | |
| SCHEMBL24309520 | 0.89 | SCN9A (0.35) | SCN9AHTR1AHTR7JAK2PCK1 | |
| SCHEMBL24309558 | 0.89 | SCN9A (0.34) | SCN9AHTR1AHTR7JAK2PCK1 | |
| SCHEMBL29566590 | 0.89 | SCN9A (0.35) | SCN9AHTR1AHTR7JAK2PCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SCN9A 385/4885HTR1A 4018/4885HTR7 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.